Known targets — ChEMBL curated mechanism
CSF1RFLT1FLT4KDRKITPDGFRAPDGFRB
The experimentally established mechanism targets of Vatalanib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 known ✓ | P17948 | 19/20 | 1.00 |
| ▸ | KDR known ✓ | P35968 | 19/20 | 1.00 |
| ▸ | PDGFRB known ✓ | P09619 | 9/20 | 1.00 |
| ▸ | KIT known ✓ | P10721 | 8/20 | 1.00 |
| ▸ | CSF1R known ✓ | P07333 | 2/20 | 1.00 |
| ▸ | FLT4 known ✓ | P35916 | 2/20 | 1.00 |
| ▸ | PDGFRA known ✓ | P16234 | 1/20 | 1.00 |
| ▸ | CIT | O14578 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | HLA-A | P04439 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 1.00 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 1.00 |
| ▸ | FRK | P42685 | 1/20 | 1.00 |
| ▸ | CDK8 | P49336 | 1/20 | 1.00 |
| ▸ | DDR1 | Q08345 | 1/20 | 1.00 |
| ▸ | STK3 | Q13188 | 1/20 | 1.00 |
| ▸ | PTK6 | Q13882 | 1/20 | 1.00 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 1.00 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 1.00 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vatalanib SCHEMBL18286 | 1.00 | FLT1 (1.00) | FLT1KDRPDGFRBKITCSF1R | |
| Vatalanib SCHEMBL28147347 | 0.99 | FLT1 (0.97) | FLT1KDRPDGFRBKITCSF1R | |
| Vatalanib SCHEMBL6131017 | 0.99 | FLT1 (0.97) | FLT1KDRPDGFRBKITCSF1R | |
| Vatalanib SCHEMBL905598 | 0.99 | FLT1 (0.97) | FLT1KDRPDGFRBKITCSF1R | |
| Vatalanib SCHEMBL6131019 | 0.99 | FLT1 (0.97) | FLT1KDRPDGFRBKITCSF1R | |
| Vatalanib SCHEMBL905616 | 0.99 | FLT1 (0.97) | FLT1KDRPDGFRBKITCSF1R | |
| Vatalanib SCHEMBL6131018 | 0.99 | FLT1 (0.97) | FLT1KDRPDGFRBKITCSF1R | |
| Vatalanib SCHEMBL29633763 | 0.99 | FLT1 (0.97) | FLT1KDRPDGFRBKITCSF1R | |
| Vatalanib SCHEMBL6605579 | 0.93 | KDR (0.88) | FLT1KDRPDGFRBKITCSF1R | |
| Vatalanib SCHEMBL6607537 | 0.92 | KDR (0.84) | FLT1KDRPDGFRBKITCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7586 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743490-A1 | HUMANIZED ANTI-CD7 ANTIBODY | Christian-Albrechts-Universität zu Kiel (DE) | 2026-05-20 | — | — | EP | claimed |
| EP-4744729-A2 | METHODS OF TREATING GASTROINTESTINAL STROMAL TUMORS | Deciphera Pharmaceuticals, LLC (US) | 2026-05-20 | — | — | EP | claimed |
| WO-2026099502-A1 | NOVEL DRUG CONJUGATES FOR TESTING CELLULAR DRUG UPTAKE | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2026-05-15 | — | — | WO | claimed |
| US-20260102468-A1 | COMPOSITIONS AND METHODS FOR MARCO INHIBITION AND IMPROVED DRUG DELIVERY | UNIV TEXAS (US) | 2026-04-16 | — | — | US | claimed |
| EP-3515892-B1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4719387-A2 | COMPLEMENT ANTIBODY-DRUG CONJUGATES | ADS Therapeutics LLC (US) | 2026-04-08 | — | — | EP | claimed |
| US-12576085-B2 | Combination comprising an ATP analog and an adenosine receptor antagonist or a nucleobase/nucleoside analog for the treatment of cancer | SAWYER MICHAEL BRUCE (CA) | 2026-03-17 | — | — | US | claimed |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| EP-4704832-A2 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | Biohaven Therapeutics Ltd. (VG) | 2026-03-11 | — | — | EP | claimed |
| US-12569575-B2 | Radiopaque particle compositions and uses thereof | GUSTAVE ROUSSY TRANSFERT (FR) | 2026-03-10 | — | — | US | claimed |
| CN-107949354-B | Coated punctal plugs | 因赛普特有限责任公司 | 2022-02-18 | — | — | CN | claimed |
| US-20220047717-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING ANTI-B7-H3 ANTIBODIES | Y-Biologics Inc. (KR) | 2022-02-17 | — | — | US | claimed |
| EP-3954373-A1 | NEOADJUVANT USE OF ANTIBODY-DRUG CONJUGATES | Immunomedics, Inc. (US) | 2022-02-16 | — | — | EP | claimed |
| EP-3953390-A1 | HUMAN ANTIBODIES THAT BIND RET AND METHODS OF USE THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2022-02-16 | — | — | EP | claimed |
| EP-3953351-A1 | CONDENSED AZINES FOR EP300 OR CBP MODULATION AND INDICATIONS THEREFOR | Plexxikon Inc. (US) | 2022-02-16 | — | — | EP | claimed |
| US-20220041704-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF EGF/EGFR PATHWAY IN COMBINATION WITH TYROSINE KINASE INHIBITORS | IN3BIO LTD. (BM) | 2022-02-10 | — | — | US | claimed |
| CN-114010787-A | Compositions and methods for treating pterygium | 拨云生物医药科技(广州)有限公司 | 2022-02-08 | — | — | CN | claimed |
| WO-2022026510-A1 | METHODS OF TREATING HER2 POSITIVE CANCER WITH TUCATINIB IN COMBINATION WITH TRASTUZUMAB, A TAXANE, AND A VEGFR-2 ANTAGONIST | SEAGEN INC. (US) | 2022-02-03 | — | — | WO | claimed |
| CN-113993898-A | Human antibodies that bind RET and methods of use thereof | 瑞泽恩制药公司 | 2022-01-28 | — | — | CN | claimed |
| CN-113967261-A | Application of FOLR1 inhibitor and medicine mixture for treating liver cancer | 中国科学院大连化学物理研究所 | 2022-01-25 | — | — | CN | claimed |